Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 5Carcinoma, Hepatocellular 2Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available 1Neoplasms 1Deafness, Autosomal Recessive 39 1Colorectal Neoplasms 1Adenocarcinoma 1

Interventions

Sorafenib 52pembrolizumab 26Nivolumab 20Bevacizumab 19Radiosurgery 17Doxorubicin 12atezolizumab 9Erlotinib Hydrochloride 9lenvatinib 8cabozantinib 7Magnetic Resonance Spectroscopy 7tremelimumab 6durvalumab 6Ramucirumab 6Radiofrequency Ablation 6Cisplatin 6Sunitinib 5tislelizumab 4regorafenib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorouracil 4Everolimus 4Capecitabine 4nintedanib 3fluoromisonidazole 3carotuximab 3bavituximab 3Tomography, X-Ray Computed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Carcinoma, Hepatocellular × tepotinib × Clear all
NCT01988493 2022-08-24

Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
117 enrolled 30 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT02115373 2022-08-24

c-Met Second-Line Hepatocellular Carcinoma

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
66 enrolled 34 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡